Table 1.

Rituximab in non-Hodgkin's lymphoma pivotal trial: infections

Patients monitored throughout treatment and >1 year follow up

Despite B cell depletion, incidence of infection was not increased

Most infections were typical of those common in normal hosts

Predominantly bacterial

Seven episodes of grade 3 infections

No patients experienced grade 4 infections

Data from McLaughlin and coworkers [1].